Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fibrin-specific thrombolytic agents.

D Collen1

  • 1Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

Annales De Biologie Clinique
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired fibrinolysis and the risk for coronary heart disease.

Circulation·1996
Same author

Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.

European journal of biochemistry·1996
Same author

Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.

Thrombosis and haemostasis·1996
Same author

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.

Circulation·1996
Same author

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Thrombosis and haemostasis·1996
Same author

Role of tissue factor in embryonic blood vessel development.

Nature·1996
Same journal

[The role of the heart-on-a-chip to drug evaluation].

Annales de biologie clinique·2026
Same journal

A morphology-driven proof-of-concept study linking interphase nuclear abnormalities to dicentric-mediated genomic instability.

Annales de biologie clinique·2026
Same journal

Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

Annales de biologie clinique·2026
Same journal

Small-cell secondary plasma cell leukemia mimicking low-grade B-cell lymphoma.

Annales de biologie clinique·2026
Same journal

[Multiple myeloma and analytical discrepancy in serum free light chain assay: a case report].

Annales de biologie clinique·2026
Same journal

[Summary of the 34th National Conference of the National College of Hospital Biochemistry].

Annales de biologie clinique·2026
See all related articles

Tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) promote clot-specific thrombolysis through distinct mechanisms. Fibrin enhances t-PA activity, while fibrin reverses scu-PA inhibition, enabling targeted fibrinolysis.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • The mammalian fibrinolytic system dissolves blood clots.
  • Plasminogen is activated to plasmin by tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA).
  • Both t-PA and single-chain u-PA (scu-PA) mediate clot-specific thrombolysis via different pathways.

Purpose of the Study:

  • To elucidate the distinct mechanisms of fibrin-specific thrombolysis by t-PA and scu-PA.
  • To compare the fibrin-specificity and efficacy of t-PA and scu-PA in preclinical and clinical settings.

Main Methods:

  • Investigated the role of fibrin in modulating plasminogen activation by t-PA and scu-PA.
  • Evaluated thrombolytic efficacy and fibrinogen sparing in animal models (pulmonary embolism, venous thrombosis, coronary artery thrombosis).

Related Experiment Videos

  • Reviewed clinical trial data for t-PA in acute myocardial infarction.

    • Main Results:

    • Fibrin significantly enhances plasminogen activation by t-PA through increased activity of fibrin-bound t-PA.
    • scu-PA's fibrin-specific thrombolysis is attributed to fibrin reversing competitive inhibition, not direct binding.
    • Both t-PA and scu-PA demonstrated thrombolytic efficacy and fibrin-specificity in animal models; t-PA showed fibrinogen sparing in human trials.

    Conclusions:

    • t-PA and scu-PA achieve fibrin-specific thrombolysis via distinct mechanisms involving fibrin.
    • Fibrin-bound t-PA exhibits enhanced plasminogen activation.
    • Fibrin facilitates scu-PA activity by overcoming competitive inhibition, supporting its use in thrombolytic therapy.